Cutaneous reactions to drugs in children

Pediatrics

Volumn 120, Issue 4, 2007, Pages

  Segal, Alissa R ^a   Doherty, Kevin M ^b   Leggott, John ^c   Zlotoff, Barrett ^c  

^a MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b Texoma Medical Center   (United States)

^c UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

Author keywords

Adverse drug reactions; Children; Cutaneous reactions; Dermatology

Indexed keywords

ALLOPURINOL; AMINOPENICILLIN; AMIODARONE; AMPICILLIN; ANTIHISTAMINIC AGENT; BARBITURIC ACID DERIVATIVE; CARBAMAZEPINE; CETIRIZINE; CORTICOSTEROID; DIPHENHYDRAMINE; DOXYCYCLINE; GRISEOFULVIN; HISTAMINE H1 RECEPTOR ANTAGONIST; HYDROCORTISONE; LIDOCAINE; MINOCYCLINE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLIN G; PHENOBARBITAL; PHENYTOIN; PYRIDOXINE; QUINIDINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULFONAMIDE; SULFONYLUREA; TETRACYCLINE; THIAZIDE DIURETIC AGENT; TRIAMCINOLONE; TUBERCULOSTATIC AGENT; UNINDEXED DRUG;

DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; EPSTEIN BARR VIRUS; ERYTHEMA MULTIFORME; FOOD AND DRUG ADMINISTRATION; HUMAN; PHOTOALLERGY; PHOTOSENSITIVITY DISORDER; PRIORITY JOURNAL; PRURITUS; RASH; REVIEW; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; URTICARIA; VIRUS INFECTION;

ADRENAL CORTEX HORMONES; ADVERSE DRUG REACTION REPORTING SYSTEMS; CHILD; DRUG ERUPTIONS; EMOLLIENTS; EXANTHEMA; HISTAMINE H1 ANTAGONISTS; HUMANS; PHOTOSENSITIVITY DISORDERS; RISK FACTORS; SERUM SICKNESS; URTICARIA;

EID: 35148864679     PISSN: 00314005     EISSN: 02105721     Source Type: Journal    
DOI: 10.1542/peds.2005-2321     Document Type: Review

References (123)

1. Cutaneous drug reaction case reports: from the world literature. Am J Clin Dermatol. 2003;4:511-521
2. Miller RR. Drug surveillance utilizing epidemiological methods: a report from the Boston Collaborative Drug Surveillance Program. Am J Hosp Pharm. 1973;30:585-592
3. Bigby M, Jick S, Jick H, Arndt K, et al. Drug-induced cutaneous reactions: a report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1975 to 1982. JAMA. 1986;256:3358-3363
4. Kushwaha KP, Verma RB, Singh YD, Rathi AK. Surveillance of drug induced diseases in children. Indian J Pediatr. 1994;61:357-365
5. Ibia EO, Schwartz RH, Wiedermann BL. Antibiotic rashes in children: survey in a private practice setting. Arch Dermatol. 2000;136:849-854
6. van der Linden PD, van der Lei J, Vlug AE, Stricker BH. Skin reactions to antibacterial agents in general practice. J Clin Epidemiol. 1998;51:703-708
7. Cirko-Begović A, Vrhovac B, Bakran I. Intensive monitoring of adverse drug reactions in infants and preschool children. Eur J Clin Pharmacol. 1989;36:63-65
8. Kramer MS, Hutchinson TA, Flegel KM, Naimark L, Contardi R, Leduc DG. Adverse drug reactions in general pediatric outpatients. J Pediatr. 1985;106:305-310
9. Johnson ML, Johnson KG, Engel A. Prevalence, morbidity, and cost of dermatologic diseases. J Am Acad Dermatol. 1984;11:930-936
10. Gruchalla R. Understanding drug allergies. J Allergy Clin Immunol. 2000;105:S637-S644
11. Pilzer JD, Burke TG, Mutnick AH. Drug allergy assessment at a university hospital and clinic. Am J Health Syst Pharm. 1996;53:2970-2975
12. Huang SW, Borum PR. Study of skin rashes after antibiotic use in young children. Clin Pediatr (Phila). 1998;37:601-607
13. Martin-Munoz F, Moreno-Ancillo A, Dominguez-Noche C, et al. Evaluation of drug-related hypersensitivity reactions in children. J Investig Allergol Clin Immunol. 1999;9:172-177
14. Preston SL, Briceland LL, Lesai TS. Accuracy of penicillin allergy reporting. Am J Health Syst Pharm. 1994;51:79-84
15. Karch FE, Lasagna L. Toward the operational identification of adverse drug reactions. Clin Pharmacol Ther. 1977;21:247-254
16. Council for International Organization of Medical Sciences. Harmonizing use of adverse drug reaction terms: definitions of terms and minimum requirements for their use - respiratory disorders and skin disorders [published correction appears in Pharmacoepidemiol Drug Saf. 1997;6:293]. Pharmacoepidemiol Drug Saf. 1997;6:115-127
17. Roujeau JC, Stern R. Medical progress: severe cutaneous reactions to drugs. N Engl J Med. 1994;331:1272-1285
18. Naranjo CA, Busto U, Sellers EM, et al. A method of estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-244
19. Kramer MS, Leventhal JM, Hutchinson TA, Feinstein AR. An algorithm for the operational assessment of adverse drug reactions: I. Background, description, and instructions for use. JAMA. 1979;242:623-632
20. Hutchinson TA, Leventhal JM, Kramer MS, Karch FE, Lipman AG, Feinstein AR. An algorithm for the operational assessment of adverse drug reactions: II. Demonstration of reproducibility and validity. JAMA. 1979;242:633-638
21. Shin HT, Chang MW. Drug eruptions in children. Curr Probl Pediatr. 2001;31:207-234
22. Litt J. Drug Eruption Reference Manual. New York, NY: Parthenon; 2000
23. Taber's Cyclopedic Medical Dictionary. Philadelphia, PA: F. A. Davis Co; 2003. Available at: www.rxlist.com. Accessed January 3, 2003.
24. Lookingbill DP, Marks JG Jr. Principles of Dermatology. Philadelphia, PA: WB Saunders; 2000
25. Litt J. The Pocketbook of Drug Eruptions and Interactions. 2nd ed. New York, NY: Parthenon; 2001
26. Rawlins MD. Clinical pharmacology: adverse reactions to drugs. Br Med J (Clin Res Ed). 1981;282:974-976
27. Assem EK. Drug allergy and tests for its detection. In: Davies DM, Ferner RE, de Glanville H, eds. Davies's Textbook of Adverse Drug Reactions. 5th ed. London, United Kingdom: Chapman & Hall Medical; 1998:791-815
28. DeShazo RD, Kemp SF. Allergic reactions to drugs and biologic agents. JAMA. 1997;278:1895-1906
29. Coombs R, Gell PGH. Classification of allergic reactions responsible for clinical hypersensitivity and disease. In: Coombs R, Gell PGH, Lachman PJ, eds. Clinical Aspects of Immunology. Oxford, United Kingdom: Blackwell Scientific; 1975:761-781
30. Sharma VK, Dhar S. Clinical pattern of cutaneous drug eruption among children and adolescents in north India. Pediatr Dermatol. 1995;12:178-183
31. Drago F, Rampini E, Rebora A. Atypical exanthems: morphology and laboratory investigations may lead to an aetiological diagnosis in about 70% of cases. Br J Dermatol. 2002;147:255-260
32. Horowitz R, Reynolds S. New oral antihistamines in pediatrics. Pediatr Emerg Care. 2004;20:143-146
33. 1-antihistamines in children. Clin Allergy Immunol. 2002;17:437-464
34. Ten Eick AP, Blumer JL, Reed MD. Safety of antihistamines in children. Drug Saf. 2001;24:119-147
35. Simons FE, Silas P, Portnoy JM, et al. Safety of cetirizine in infants 6 to 11 months of age: a randomized, double-blind, placebo-controlled study. J Allergy Clin Immunol. 2003;111:1244-1248
36. Tamayo-Sanchez L, Ruiz-Maldonado R, Laterza A. Acute annular urticaria in infants and children. Pediatr Dermatol. 1997;14:231-234
37. Kanwar AJ, Greaves MW. Approach to the patient with chronic urticaria. Hosp Pract. 1996;31:175-179, 183-184, 187-189
38. Kuby J. Immunology. In: Allen D, Julet MR, Maass DC, eds. Hypersensitive Reactions. 3rd ed. New York, NY: WH Freeman; 1997:413-438
39. Solley GO, Gleich GJ, Jordon RE, Schroeter AL. The late phase of the immediate wheal and flare skin reaction: its dependence upon IgE antibodies. J Clin Invest. 1976;58:408-420
40. Carder KR. Hypersensitivity reactions in neonates and infants. Dermatol Ther. 2005;18:160-175
41. Mortureux P, Léauté-Labrèze C, Legrain-Lifermann V, Lamireau T, Sarlangue J, Taïeb A. Acute urticaria in infancy and early childhood: a prospective study. Arch Dermatol. 1998;134:319-323
42. Legrain V, Taïeb A, Sage T, Maleville J. Urticaria in infants: a study of forty patients. Pediatr Dermatol. 1990;7:101-107
43. Balaban J. Medicaments as the possible cause of urticaria in children. Acta Dermatovenerol Croat. 2002;10:155-159
44. Sackesen C, Sekerel BE, Orhan F, et al. The etiology of different forms of urticaria in childhood. Pediatr Dermatol. 2004;21:102-108
45. Schuller DE. Acute urticaria in children: causes and an aggressive diagnostic approach. Postgrad Med. 1982;72:179-185
46. Sakurai M, Oba M, Matsumoto K, Tokura Y, Furukawa F, Takigawa M. Acute infectious urticaria: clinical and laboratory analysis in nineteen patients. J Dermatol. 2000;27:87-93
47. Bilbao A, Garcia JM, Pocheville I, et al. Round table: urticaria in relation to infections [in Spanish]. Allergol Immunopathol (Madr). 1999;27:73-85
48. Apter AJ, Kinman JL, Bilker WB, et al. Is there cross-reactivity between penicillins and cephalosporins? Am J Med. 2006;119:354.e11-354.e19
49. Twarog FJ. Urticaria in childhood: pathogenesis and management. Pediatr Clin North Am. 1983;30:887-898
50. Kennard CD, Ellis CN. Pharmacologic therapy for urticaria. J Am Acad Dermatol. 1991;25:176-187
51. Smith PF, Corelli RL. Doxepin in the management of pruritus associated with allergic cutaneous reactions. Ann Pharmacother. 1997;31:633-635
52. Poon M, Reid C. Do steroids help children with acute urticaria? Arch Dis Child. 2004;89:85-86
53. Zuberbier T, Ifflander J, Semmler C, Henz BM. Acute urticaria: clinical aspects and therapeutic responsiveness. Acta Derm Venereol. 1996;76:295-297
54. Henderson RL Jr, Fleischer AB Jr, Feldman SR. Allergists and dermatologists have far more expertise in caring for patients with urticaria than other specialists. J Am Acad Dermatol. 2000;43:1084-1091
55. Mahboob A, Haroon TS. Drugs causing fixed eruptions: a study of 450 cases. Int J Dermatol. 1998;37:833-838
56. Morelli JG, Tay YK, Rogers M, Halbert A, Krafchik B, Weston WL. Fixed drug eruptions in children. J Pediatr. 1999;134:365-367
57. Lee AY. Topical provocation in 31 cases of fixed drug eruption: change of causative drugs in 10 years. Contact Dermatitis. 1998;38:258-260
58. Ozkaya-Bayazit E. Specific site involvement in fixed drug eruption. J Am Acad Dermatol. 2003;49:1003-1007
59. Sharma VK, Dhar S, Gill AN. Drug related involvement of specific sites in fixed eruptions: a statistical evaluation. J Dermatol. 1996;23:530-534
60. Thankappan TP, Zachariah J. Drug-specific clinical pattern in fixed drug eruptions. Int J Dermatol. 1991;30:867-870
61. Nussinovitch M, Prais D, Ben-Amitai D, Amir J, Volovitz B. Fixed drug eruption in the genital area in 15 boys. Pediatr Dermatol. 2002;19:216-219
62. Brown SG. Fixed drug eruptions in deeply pigmented subjects: clinical observations on 350 patients. Br Med J. 1964;2(5416):1041-1044
63. Dhar S, Sharma VK. Fixed drug eruption due to ciprofloxacin. Br J Dermatol. 1996;134:156-158
64. Tham SN, Kwok YK, Chan HL. Cross-reactivity in fixed drug eruptions to tetracyclines. Arch Dermatol. 1996;132:1134-1135
65. Chan HL, Tan KC. Fixed drug eruption to three anticonvulsant drugs: an unusual case of polysensitivity. J Am Acad Dermatol. 1997;36:259
66. Tornero P, De Barrio M, Baeza ML, Herrero T. Cross-reactivity among p-amino group compounds in sulfonamide fixed drug eruption: diagnostic value of patch testing. Contact Dermatitis. 2004;51:57-62
67. Kanwar AJ, Bharija SC, Singh M, Belhaj MS. Ninety-eight fixed drug eruptions with provocation tests. Dermatologica. 1988;177:274-279
68. Selvaag E. Clinical drug photosensitivity: a retrospective analysis of reports to the Norwegian Adverse Drug Reactions Committee from the years 1970-1994. Photodermatol Photoimmunol Photomed. 1997;13:21-23
69. Bligard CA, Storer JS. Photosensitivity in infants and children. Dermatol Clin. 1986;4:311-319
70. Moore DE. Drug-induced cutaneous photosensitivity: incidence, mechanism, prevention and management. Drug Saf. 2002;25:345-372
71. Drugs that cause photosensitivity. Med Lett Drugs Ther. 1995;37:35-36
72. Ernst E, Rand JI, Barnes J, Stevinson C. Adverse effects profile of the herbal antidepressant St. John's wort (Hypericum perforatum L.). Eur J Clin Pharmacol. 1998;54:589-594
73. Harth Y, Rapoport M. Photosensitivity associated with antipsychotics, antidepressants and anxiolytics. Drug Saf. 1996;14:252-259
74. Vassileva SG, Mateev G, Parish LC. Antimicrobial photosensitive reactions. Arch Intern Med. 1998;158:1993-2000
75. Fotiades J, Soter NA, Lim HW. Results of evaluation of 203 patients for photosensitivity in a 7.3-year period. J Am Acad Dermatol. 1995;33:597-602
76. Lawley TJ, Bielory L, Gascon P, Yancey KB, Young NS, Frank MM. A prospective clinical and immunologic analysis of patients with serum sickness. N Engl J Med. 1984;311:1407-1413
77. Sanklecha MU. Cefaclor induced serum sickness like reaction. Indian J Pediatr. 2002;69:921
78. Martin J, Abbott G. Serum sickness like illness and antimicrobials in children. N Z Med J. 1995;108:123-124
79. Hebert AA, Sigman ES, Levy ML. Serum sickness-like reactions from cefaclor in children. J Am Acad Dermatol. 1991;25:805-808
80. Levine LR. Quantitative comparison of adverse reactions to cefaclor vs. amoxicillin in a surveillance study. Pediatr Infect Dis. 1985;4:358-361
81. Platt R, Dreis MW, Kennedy DL, Kuritsky JN. Serum sickness-like reactions to amoxicillin, cefaclor, cephalexin, and trimethoprim-sulfamethoxazole. J Infect Dis. 1988;158:474-477
82. Heckbert SR, Stryker WS, Coltin KL, Manson JE, Platt R. Serum sickness in children after antibiotic exposure: estimates of occurrence and morbidity in a health maintenance organization population. Am J Epidemiol. 1990;132:336-342
83. Kearns GL, Wheeler JG, Childress SH, Letzig LG. Serum sickness-like reactions to cefaclor: role of hepatic metabolism and individual sensitivity. J Pediatr. 1994;125:805-811
84. Rosenfeld RM, Culpepper L, Doyle KJ, et al. Clinical practice guideline: otitis media with effusion. Otolaryngol Head Neck Surg. 2004;130(5 suppl):S95-S118
85. Parshuram CS, Phillips RJ. Retrospective review of antibiotic-associated serum sickness in children presenting to a paediatric emergency department. Med J Aust. 1998;169:116
86. Shapiro LE, Knowles SR, Shear NH. Comparative safety of tetracycline, minocycline, and doxycycline. Arch Dermatol. 1997;133:1224-1230
87. Harel L, Amir J, Livni E, Straussberg R, Varsano I. Serum-sickness-like reaction associated with minocycline therapy in adolescents. Ann Pharmacother. 1996;30:481-483
88. Slama TG. Serum sickness-like illness associated with ciprofloxacin. Antimicrob Agents Chemother. 1990;34:904-905
89. Parra FM, Pérez Elias MJ, Cuevas M, Ferreira A. Serum sickness-like illness associated with rifampicin. Ann Allergy. 1994;73:123-125
90. Colton RL, Amir J, Mimouni M, Zeharia A. Serum sickness-like reaction associated with griseofulvin. Ann Pharmacother. 2004;38:609-611
91. McCollom RA, Elbe DH, Ritchie AH. Bupropion-induced serum sickness-like reaction. Ann Pharmacother. 2000;34:471-473
92. Peloso PM, Baillie C. Serum sickness-like reaction with bupropion. JAMA. 1999;282:1817
93. Waibel KH, Katial RK. Serum sickness-like reaction and bupropion. J Am Acad Child Adolesc Psychiatry. 2004;43:509
94. Park H, Knowles S, Shear NH. Serum sickness-like reaction to itraconazole. Ann Pharmacother. 1998;32:1249
95. Shapiro LE, Knowles SR, Shear NH. Fluoxetine-induced serum sickness-like reaction. Ann Pharmacother. 1997;31:927
96. Revuz J. New advances in severe adverse drug reactions. Dermatol Clin. 2001;19:697-709
97. Knowles S, Shapiro L, Shear NH. Serious dermatologic reactions in children. Curr Opin Pediatr. 1997;9:388-395
98. Garcia-Doval I, LeCleach L, Bocquet H, Otero XL, Roujeau JC. Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death? Arch Dermatol. 2000;136:323-327
99. Kaur S, Sarkar R, Thami GP, Kanwar AJ. Anticonvulsant hypersensitivity syndrome. Pediatr Dermatol. 2002;19:142-145
100. Carroll MC, Yueng-Yue KA, Esterly NB, Drolet BA. Drug-induced hypersensitivity syndrome in pediatric patients. Pediatrics. 2001;108:485-492
101. Rzany B, Hering O, Mockenhaupt M, et al. Histopathological and epidemiological characteristics of patients with erythema exudativum multiforme major, Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol. 1996;135:6-11
102. Auquier-Dunant A, Mockenhaupt M, Naldi L, et al. Severe cutaneous adverse reactions: correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis - results of an international prospective study. Arch Dermatol. 2002;138:1019-1024
103. Léauté-Labrèze C, Lamireau T, Chawki D, Maleville J, Taïeb A. Diagnosis, classification, and management of erythema multiforme and Stevens-Johnson syndrome. Arch Dis Child. 2000;83:347-352
104. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993;129:92-96
105. Chan HL, Stern RS, Arndt KA, et al. The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis: a population-based study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol. 1990;126:43-47
106. Hurwitz S. Erythema multiforme: a review of its characteristics, diagnostic criteria, and management. Pediatr Rev. 1990;11:217-222
107. Villiger RM, von Vigier RO, Ramelli GP, Hassink RI, Bianchetti MG. Precipitants in 42 cases of erythema multiforme. Eur J Pediatr. 1999;158:929-932
108. Tay YK, Huff JC, Weston WL. Mycoplasma pneumoniae infection is associated with Stevens-Johnson syndrome not erythema multiforme (von Hebra). J Am Acad Dermatol. 1996;35:757-760
109. Weston WL. What is erythema multiforme? Pediatr Ann. 1996;25:106-109
110. Carrozzo M, Togliatto M, Gandolfo S. Erythema multiforme: a heterogeneous pathologic phenotype [in Italian]. Minerva Stomatol. 1999;48:217-226
111. Schalock PC, Dinulos JGH, Pace N, Schwarzenberger K, Wegner JK. Erythema multiforme due to Mycoplasma pneumoniae infection in two children. Pediatr Dermatol. 2006;23:546-555
112. Assier H, Bastuji-Garin S, Revuz J, Roujeau JC. Erythema multiforme with mucous membrane involvement and Stevens-Johnson syndrome are clinically different disorders with distinct causes. Arch Dermatol. 1995;131:539-543
113. Schöpf E, Stühmer A, Rzany B, Victor N, Zentgraf R, Kapp JF. Toxic epidermal necrolysis and Stevens-Johnson syndrome: an epidemiologic study from West Germany. Arch Dermatol. 1991;127:839-842
114. Ginsburg CM. Stevens-Johnson syndrome in children. Pediatr Infect Dis. 1982;1:155-158
115. Revuz J, Penso D, Roujeau JC, et al. Toxic epidermal necrolysis: clinical findings and prognosis factors in 87 patients. Arch Dermatol. 1987;123:1160-1165
116. Guillaume JC, Roujeau JC, Revuz J, Penso D, Touraine R. The culprit drugs in 87 cases of toxic epidermal necrolysis (Lyell's syndrome). Arch Dermatol. 1987;123:1166-1170
117. Prendiville JS, Hebert AA, Greenwald MJ, Esterly NB. Management of Stevens-Johnson syndrome and toxic epidermal necrolysis in children. J Pediatr. 1989;115:881-887
118. Fritsch PO, Sidoroff A. Drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis. Am J Clin Dermatol. 2000;1:349-360
119. Sharma VK, Sethuraman G, Kumar B. Cutaneous adverse drug reactions: clinical pattern and causative agents - a 6 year series from Chandigarh, India. J Postgrad Med. 2001;47:95-99
120. Rademaker M, Oakley A, Duffil MB. Cutaneous adverse reactions to drugs in the hospital setting. N Z Med J. 1995;108:165-166
121. Ponvert C, Le Clainche L, de Blic J, Le Bourgeois M, Scheinmann P, Paupe J. Allergy to beta-lactam antibiotics in children. Pediatrics. 1999;104(4). Available at: www.pediatrics.org/cgi/content/full/104/4/e45
122. Salkind AR, Cuddy PG, Foxworth JW. The rational clinical examination: is this patient allergic to penicillin? An evidence-based analysis of the likelihood of penicillin allergy. JAMA. 2001;285:2498-2505
123. Elias SS, Patel NM, Cheigh NH. Drug induced skin reactions. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: A Pathophysiologic Approach. 5th ed. Norwalk, CT: Appleton and Lange; 2002:1705-1716